[1] Fletcher C D M,Bridge J A,Hogendoorn P C W,et al.WHO classification of tumours of soft tissue and bone[M]. Lyon: IARC Press,2013:271-272.
[2] Kerketa M, Shah N, Kundu S, et al. Clinicopathological and histological behavior of mesenchymal chondrosarcoma involving maxilla[J]. J Oral Maxillofac Pathol, 2017, 21:132-135.
[3] Schneiderman B A, Kliethermes S A, Nystrom L M. Survival in mesenchymal chondrosarcoma varies based on age and tumor location: a survival analysis of the SEER database [J]. Clin Orthop Relat Res, 2017, 475: 799-805.
[4] Tien N, Chaisuparat R, Fernandes R, et al. Mesenchymal chondrosarcoma of the maxilla: case report and literature review[J]. J Oral Maxillofac Surg, 2007, 65(6):1260-1266.
[5] Arora K,Riddle N D.Extraskeletal mesenchymal chondrosarcoma [J].Arch Pathol Lab Med,2018,142(11):1421-1424.
[6] 庞宗国,何兴状,吴兰雁,等. 间叶性软骨肉瘤23例临床病理和免疫表型分析[J].中华病理学杂志,2011,40(6):368-372.
[7] Machado I, Yoshida A, Morales M G N, et al. Review with novel markers facilities precise categorization of 41 cases of diagnostically challenging, “undifferentiated small round cell tumors.” A clinicopathologic, immunophenotypic and molecular analysis[J].Ann Diagn Pathol,2018,34:1-12.
[8] Wehrli B M, Huang W, De Crombrugghe B, et al. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors[J]. Human Pathology,2003,34(3):263-269.
[9] Cajaiba M M, Luo J H, Goodman M A, et al. SOX9 expression is not limited to chondroid neoplasms: variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas[J]. Int J Surg Pathol, 2010,18(5):319-323.
[10] Yoshida K, Machado I, Motoi T, et al. NKX3.1 is a useful immunohistochemical marker of EWSR1-NFATC2 sarcoma and mesenchymal chondrosarcoma[J]. Am J Surg Pathol, 2020,44:719-28.
[11] Syed M, Mushtaq S, Loya A, et al. NKX3.1 a useful marker for mesenchymal chondrosarcoma: an immunohistochemical study[J]. Ann Diagn Pathol,2020,50:151660.
[12] Wang L, Motoi T, Khanin R, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data[J]. Gene Chromosome Canc,2012, 51(2):127-139.
[13] El Beaino M, Roszik J, Livingston J A, et al. Mesenchymal chondrosarcoma: a review with emphasis on its fusion-driven biology[J]. Curr Oncol Rep,2018, 20(5):37.
[14] De Amorim Bernstein K, Liebsch N, Chen Y L,et al. Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas[J]. J Surg Oncol,2016,114(8):982-986.
[15] Choo C S, Wan Abdul Rahman W F, Jaafar H, et al. Mesenchymal chondrosarcoma of maxilla in paediatric patient[J]. BMJ Case Reports, 2019, 12(3):e228969.
[16] 张鲲鹏,孙 斌,邹 泓. 上颌骨不同病理亚型软骨肉瘤治疗方案的系统评价[J].重庆医学,2019,48(10):1726-1731.